Price Chart

Executive Summary

Artiva Biotherapeutics announced positive initial Phase 2a data for AlloNK in refractory RA, showing 71% ACR50 at six months in its company-sponsored trial, and FDA alignment on a single registrational Phase 3 trial expected to start H2 2026. The data supports AlloNK's potential as an off-the-shelf deep B-cell depleting therapy with a favorable outpatient tolerability profile, de-risking the path to a BLA submission in 2029.

Key Facts

• 71% ACR50 response at six months in company-sponsored Phase 2a basket trial (5 of 7 patients) in refractory RA.
• FDA alignment on a single registrational Phase 3 trial for AlloNK in refractory RA, with ACR50 at six months as primary endpoint.
• Phase 3 trial expected to enroll ~150 patients, randomized 2:1 AlloNK+rituximab vs rituximab alone, with crossover option.
• No CRS, ICANS, or treatment discontinuations observed in autoimmune patients; tolerability supports outpatient community administration.
• More than 70 autoimmune patients treated with AlloNK across >40 active clinical sites, mostly in community settings.
• B-cell depletion observed uniformly by Day 13 in all 51 evaluable patients; B-cell reconstitution shows naïve/transitional predominance consistent with 'reset'.
• Initial data in Sjögren disease (n=7 at 6 months) and systemic sclerosis (n=4 at 6 months) show consistent clinical improvements.
• Artiva expects to initiate Phase 3 in H2 2026, report primary efficacy data in H2 2028, and submit BLA in 2029.
• Artiva estimates 150,000-200,000 refractory RA patients in the U.S. who have failed ≥2 b/tsDMARDs, with only 11-19% ACR50 likelihood on current therapies.

Financial Impact

No financial data provided in press release; market cap ~$309M. Positive clinical data and FDA alignment likely to increase valuation if Phase 3 succeeds.

Risk Factors

• Phase 3 trial may fail to meet primary endpoint or show safety issues in a larger population.
• FDA minutes from recent interaction could include requests for additional data or different trial design.
• Competition from other deep B-cell depleting therapies (e.g., CAR-T, bispecifics) could limit market share.
• Artiva will need additional financing to complete Phase 3 and BLA submission; dilution risk exists.
• Pooled data from separate trials (company-sponsored and IIT) may not be directly comparable.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status